The White House has set a one-month deadline for drug manufacturers to negotiate lower prices. If they fail to do so, the ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

The Legislature and Gov. Maura Healey last year enacted a pair of new health policy laws, including one aimed at reining in ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

President Trump could have walked softly and carried a big stick. As pharmaceutical investors see it, he instead stomped ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

The company had also said last month that Paul Stoffels, a pharma legend who took on the CEO role in 2022 in a bid to ...